99mTc carbonyl t-butyl isonitrile: a potential new agent for myocardial perfusion imaging.
OBJECTIVE
The recent development of mixed ligand complexes using a 99mTc tricarbonyl synthon has prompted us to revisit the first generation product, 99mTc-t-butyl isonitrile (TBI), for possible myocardial imaging after modification of the 99mTc core to a mixed ligand core of carbonyl and t-butyl isonitrile. The easy availability of TBI from commercial sources and the recent promising development of a 'kit' procedure to prepare the 99mTc tricarbonyl aqua synthon/precursor [99mTc(H2O)3(CO)3]+ were other factors that triggered this work.


METHODS
The carbonyl precursor (37-370 MBq/0.5 ml) was synthesized and reacted with TBI (3 mg.ml-1) at room temperature and at pH 8 for 1 h. [99mTc(CO)3(TBI)3]+ was characterized by C18 reverse phase HPLC in gradient mode with water and acetonitrile as solvent. Biodistribution studies were carried out in normal mice and planar images were acquired in rabbit at 5 min, 30 min, 1 h, 2 h and 4 h post-injection to assess heart uptake and soft tissue retention. [99mTc(CO)3(TBI)3]+was formed as a single species in >95% yield and was found to be stable. Biodistribution studies in mice revealed 2.3 (+/-0.2)% uptake in heart at 5 min p.i. with heart/liver, heart/lung and heart/blood ratios of 1.5, 2.0 and 30, respectively. Imaging studies in rabbits showed high uptake in myocardium, with negligible activity in blood and lungs, at 5 min p.i. that washed out of the heart after 4 h.


CONCLUSIONS
[99mTc(CO)3(TBI)3]+ could be prepared in >95% yields. The complex showed high myocardial uptake with desirable rate of washout from heart in rabbits. [99mTc(CO)3(TBI)3]+ has potential to extend to larger animal studies and later for clinical evaluation as a myocardial imaging agent.
Kothari
Kanchan K
KK
Radiopharmaceuticals Division, Isotope Group, Bhabha Atomic Research Centre, Mumbai, India. kanchan@apsara.barc.ernet.in
Satpati
Drishty
D
Joshi
Sangeeta
S
Venkatesh
Meera
M
Ramamoorthy
Natesan
N
Pillai
Maroor R A
MR
D000818:Animals; D005240:Feasibility Studies; D006321:Heart / Q000000981:diagnostic imaging*; D008657:Metabolic Clearance Rate; D051379:Mice; D009206:Myocardium / Q000378:metabolism*; D009570:Nitriles / Q000493:pharmacokinetics*; D009928:Organ Specificity; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D011817:Rabbits; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D014018:Tissue Distribution
D009570:Nitriles; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; C043714:technetium Tc 99m hexakis(tert-butylisonitrile)